These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 35989139)

  • 1. Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives.
    Bouligny IM; Maher KR; Grant S
    Blood Rev; 2023 Jan; 57():100996. PubMed ID: 35989139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia.
    Wang A; Zhong H
    Hematology; 2018 Dec; 23(10):729-739. PubMed ID: 29902132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microenvironment in acute myeloid leukemia: focus on senescence mechanisms, therapeutic interactions, and future directions.
    Guarnera L; Santinelli E; Galossi E; Cristiano A; Fabiani E; Falconi G; Voso MT
    Exp Hematol; 2024 Jan; 129():104118. PubMed ID: 37741607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment.
    Kogan AA; Lapidus RG; Baer MR; Rassool FV
    Adv Cancer Res; 2019; 141():213-253. PubMed ID: 30691684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities.
    Bruno S; Mancini M; De Santis S; Monaldi C; Cavo M; Soverini S
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia.
    Skelding KA; Barry DL; Theron DZ; Lincz LF
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways.
    Bakhtiyari M; Liaghat M; Aziziyan F; Shapourian H; Yahyazadeh S; Alipour M; Shahveh S; Maleki-Sheikhabadi F; Halimi H; Forghaniesfidvajani R; Zalpoor H; Nabi-Afjadi M; Pornour M
    Cell Commun Signal; 2023 Sep; 21(1):252. PubMed ID: 37735675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia.
    Allert C; Müller-Tidow C; Blank MF
    Int J Cancer; 2024 Jan; 154(2):197-209. PubMed ID: 37565773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Microenvironment in Acute Myeloid Leukemia: Adjusting Niches.
    Menter T; Tzankov A
    Front Immunol; 2022; 13():811144. PubMed ID: 35273598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.
    Gojo I; Karp JE
    Clin Cancer Res; 2014 Dec; 20(24):6233-41. PubMed ID: 25324141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia.
    Humphries S; Bond DR; Germon ZP; Keely S; Enjeti AK; Dun MD; Lee HJ
    Clin Epigenetics; 2023 Sep; 15(1):150. PubMed ID: 37705055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New strategies for relapsed acute myeloid leukemia: fertile ground for translational research.
    Dinner SN; Giles FJ; Altman JK
    Curr Opin Hematol; 2014 Mar; 21(2):79-86. PubMed ID: 24419335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia.
    Kirtonia A; Pandya G; Sethi G; Pandey AK; Das BC; Garg M
    J Mol Med (Berl); 2020 Aug; 98(8):1069-1091. PubMed ID: 32620999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting transcription factors in acute myeloid leukemia.
    Takei H; Kobayashi SS
    Int J Hematol; 2019 Jan; 109(1):28-34. PubMed ID: 29956082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Microenvironment in Resistance to Therapy in AML.
    Tabe Y; Konopleva M
    Curr Hematol Malig Rep; 2015 Jun; 10(2):96-103. PubMed ID: 25921386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute myeloid leukemia in the vascular niche.
    Cogle CR; Bosse RC; Brewer T; Migdady Y; Shirzad R; Kampen KR; Saki N
    Cancer Lett; 2016 Oct; 380(2):552-560. PubMed ID: 25963886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia.
    Ladikou EE; Sivaloganathan H; Pepper A; Chevassut T
    Curr Oncol Rep; 2020 Feb; 22(3):27. PubMed ID: 32048054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia.
    Tao YF; Xu LX; Lu J; Hu SY; Fang F; Cao L; Xiao PF; Du XJ; Sun LC; Li ZH; Wang NN; Su GH; Li YH; Li G; Zhao H; Li YP; Xu YY; Zhou HT; Wu Y; Jin MF; Liu L; Zhu XM; Ni J; Wang J; Xing F; Zhao WL; Pan J
    J Exp Clin Cancer Res; 2015 Jan; 34(1):4. PubMed ID: 25609158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the microenvironment in acute myeloid leukemia.
    Rashidi A; Uy GL
    Curr Hematol Malig Rep; 2015 Jun; 10(2):126-31. PubMed ID: 25921388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic targeting and personalized approaches for AML.
    Roboz GJ
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):44-51. PubMed ID: 25696833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.